Polar Capital has launched a global biotechnology fund for recent hire David Pinniger, as it seeks to build on its formidable reputation in the space.
Pinniger joined the healthcare team in June from SV Life Sciences, together with ex-AXA healthcare manager Deane Donnigan. Both managers have a long standing background in biotechnology: Donnigan managed the Framlington Healthcare and Biotechnology funds, while Pinniger was in charge of the International Biotechnology trust. The new vehicle, Polar Capital Biotechnology fund, is open-ended and will hold between 40 and 60 stocks; performance will be benchmarked against the NASDAQ Biotechnology index. The fund has an annual AMC of 1.5% on the retail share class and 1% for institutions...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
